
Yahoo · 9 de sept de 2026
Johnson & Johnson (NYSE:JNJ) has secured Chinese approval for Icotyde, its once-daily oral treatment for moderate-to-severe plaque psoriasis. The decision gives…
AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Últimos 200 días · 12/11/25 — 09/09/26
+15.71%
Precio
$ 40.180
Var. %
+0,34%
Volumen operado
141
Precio ABBV
US$ 252,48
Teórico (precio / ratio)
ABBV ÷ 10
US$ 25,25
Sí, existe el CEDEAR de ABBV (AbbVie Inc.) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es ABBV.
El ticker del CEDEAR de AbbVie Inc. en Argentina es ABBV. La acción subyacente cotiza en NYSE con el símbolo ABBV.
El CEDEAR ABBV tiene un ratio de 10:1. Eso significa que 10 CEDEARs equivalen a 1 acción de ABBV.
El CEDEAR ABBV cotiza hoy a $ 40.180 en pesos argentinos, con una variación diaria de +0,34%.
La acción subyacente ABBV (AbbVie Inc.) cotiza a US$ 252,48 en su mercado de origen (NYSE).

Yahoo · 9 de sept de 2026
Johnson & Johnson (NYSE:JNJ) has secured Chinese approval for Icotyde, its once-daily oral treatment for moderate-to-severe plaque psoriasis. The decision gives…

Yahoo · 9 de sept de 2026
On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ:APGE) for $135.11 per share in cas…

Yahoo · 9 de sept de 2026
Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was…
Precio de cierre en pesos argentinos. Fuente: data912.
Cotización
US$ 26,17
vs teórico
+3,65%
Cotización MEP implícita
$ 1.535,35
Cotización
US$ 26,15
vs teórico
+3,57%
Cotización Cable implícita
$ 1.536,52
El precio teórico del CEDEAR ABBV se calcula dividiendo el precio de ABBV por el ratio (10). Hoy resulta en US$ 25,25.
En BYMA podés operar ABBV en pesos, ABBVD en dólar MEP y ABBVC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR ABBV en pesos argentinos, con datos de data912.

Yahoo · 9 de sept de 2026
AbbVie (NYSE:ABBV) executives outlined growth plans across immunology, oncology and neuroscience at a Wells Fargo conference, emphasizing continued momentum for…

Yahoo · 9 de sept de 2026
By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) said it appointed Raju Willener as Chief Financial Officer, having previously served as Director of Corporate De…

SeekingAlpha · 9 de sept de 2026
AbbVie Inc. (ABBV) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 10:15 AM EDTCompany ParticipantsScott Reents - Executive VP &...

Yahoo · 9 de sept de 2026
LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.
Benzinga · 9 de sept de 2026
- conference call
Noticias vía Finnhub